2-Methyl-1-[2-(ethylsulfonyl)ethyl]-5-nitro-1H-imidazole

The final metabolite is sodium bicarbonate, which can correct metabolic acidosis; when hyperkalemia is accompanied by acidosis, it can correct acidosis and allow potassium ions to enter the cells from the blood and extracellular fluid.

Under normal circumstances, human blood also contains a small amount of lactic acid, which is mainly produced by glucose or glycogenolysis, and comes from muscles, skin, brain and cells. After lactic acid is produced, it may be converted into glycogen or acetic acid, or enter the tricarboxylic acid cycle and be decomposed into water and carbon dioxide. Therefore, the final metabolite of sodium lactate is sodium bicarbonate, which can correct metabolic acidosis. When hyperkalemia is accompanied by acidosis, sodium lactate can correct acidosis and allow potassium ions to enter cells from blood and extracellular fluid. The main organs that degrade lactic acid are liver and kidney. When lactic acid metabolism in the body is abnormal or impaired, the therapeutic effect is poor.

When hyperkalemia is accompanied by acidosis, sodium lactate can cause potassium ions to enter cells from the blood and extracellular fluid.

Under normal circumstances, human blood also contains a small amount of lactic acid, which is mainly produced by glucose or glycogenolysis, and comes from muscles, skin, brain and cells. After lactic acid is produced, it may be converted into glycogen or acetic acid, or enter the tricarboxylic acid cycle and be decomposed into water and carbon dioxide. Therefore, the final metabolite of sodium lactate is sodium bicarbonate, which can correct metabolic acidosis. When hyperkalemia is accompanied by acidosis, sodium lactate can correct acidosis and allow potassium ions to enter cells from blood and extracellular fluid. The main organs that degrade lactic acid are liver and kidney. When lactic acid metabolism in the body is abnormal or impaired, the therapeutic effect is poor.

Fluconazole is a triazole broad-spectrum antifungal drug that inhibits the reproduction and growth of fungi by highly selectively inhibiting the C-14-alpha;-demethylation of fungal cytochrome P-450 sterols, causing the accumulation of 14-alpha;-methyl sterols in fungi. In vitro tests have shown that this product has antibacterial activity against Cryptococcus neoformans and Candida species. Oral and intravenous injection of fluconazole in animals is effective in the following animal fungal infection models: Candida infection (including systemic candidiasis in immunodeficient animals); Cryptococcus neoformans infection (including intracranial infection); Microsporum and Trichophyton infection, etc. Fluconazole is also effective against Blastomyces dermatitidis infection and Coccidioides immitis infection (including intracranial infection); and is also effective against infections caused by Histoplasma capsulatum in normal animals and immunosuppressed animals.

It gradually releases iodine to exert its antibacterial effect, causing bacterial protein to denature and die, and is effective against bacteria, fungi, and viruses. Its characteristic is that it has little irritation to tissues.

This product is a broad-spectrum aminoglycoside antibiotic, and its mechanism of action is mainly to inhibit bacterial protein synthesis. It has antibacterial effects on common Gram-negative bacteria in the eye.